Is ipilimumab a monoclonal antibody?

Ipilimumab (Yervoy, developed by Medarex and Bristol-Myers Squibb) is a fully human monoclonal IgG1κ antibody against the cytotoxic T-lymphocyte antigen-4 (CTLA-4), an immune-inhibitory molecule expressed in activated T cells and in suppressor T regulatory cells.

What cancer is ipilimumab used for?

YERVOY® (ipilimumab) is a prescription medicine used in adults and children 12 years of age and older to treat melanoma (a kind of skin cancer) that has spread (metastatic) or cannot be removed by surgery (unresectable).

What is ipilimumab immunotherapy?

Immunotherapy is cancer treatment that stimulates the body’s immune system to fight cancer, such as melanoma, anywhere in the body. Immunotherapy is systemic, which means that the treatments reach all parts of your body through the bloodstream.

How was ipilimumab developed?

Following preclinical studies of CTLA-4 blockade in murine tumor models, ipilimumab was developed as a fully human monoclonal antibody and evaluated in several clinical trials. These trials included two randomized, controlled phase III trials in which ipilimumab demonstrated an improvement in OS.

Who makes ipilimumab?

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult …

Is ipilimumab targeted therapy?

Ipilimumab is classified as a monoclonal antibody. Monoclonal antibodies are a relatively new type of “targeted” cancer therapy. Antibodies are an integral part of the body’s immune system.

How often is ipilimumab given?

Ipilimumab is now approved worldwide and is one of the most common drugs used as front-line treatment for metastatic melanoma. The approved dose and schedule for ipilimumab is 3 mg/kg infused over 90 minutes administered every 3 weeks for up to four doses.

Who invented ipilimumab?

Dr. James Allison is credited for the discovery of ipilimumab.

Is ipilimumab FDA approved?

FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma. On October 2, 2020, the Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.)